Btr Capital Management Inc buys $7,392,266 stake in Gilead Sciences (GILD)

Gilead Sciences (GILD) : Btr Capital Management Inc scooped up 2,235 additional shares in Gilead Sciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 15, 2016. The investment management firm now holds a total of 85,037 shares of Gilead Sciences which is valued at $7,392,266.Gilead Sciences makes up approximately 1.64% of Btr Capital Management Inc’s portfolio.

Other Hedge Funds, Including , Cedar Hill Associates sold out all of its stake in GILD during the most recent quarter. The investment firm sold 35,783 shares of GILD which is valued $3,110,616.Capital Analysts reduced its stake in GILD by selling 329 shares or 2.17% in the most recent quarter. The Hedge Fund company now holds 14,814 shares of GILD which is valued at $1,287,781. Gilead Sciences makes up approx 0.25% of Capital Analysts’s portfolio.Naples Global Advisors reduced its stake in GILD by selling 4,848 shares or 50.56% in the most recent quarter. The Hedge Fund company now holds 4,740 shares of GILD which is valued at $406,455. Gilead Sciences makes up approx 0.16% of Naples Global Advisors’s portfolio.Mazama Capital Management Inc reduced its stake in GILD by selling 1,347 shares or 1.83% in the most recent quarter. The Hedge Fund company now holds 72,390 shares of GILD which is valued at $6,265,355. Gilead Sciences makes up approx 1.23% of Mazama Capital Management Inc’s portfolio. Iowa State Bank added GILD to its portfolio by purchasing 136 company shares during the most recent quarter which is valued at $11,771. Gilead Sciences makes up approx 0.01% of Iowa State Bank’s portfolio.

Gilead Sciences opened for trading at $86.94 and hit $87.34 on the upside on Monday, eventually ending the session at $86.93, with a gain of 0.30% or 0.26 points. The heightened volatility saw the trading volume jump to 67,88,252 shares. Company has a market cap of $115,775 M.

On the company’s financial health, Gilead Sciences reported $3.03 EPS for the quarter, missing the analyst consensus estimate by $ -0.10 based on the information available during the earnings call on Apr 28, 2016. Analyst had a consensus of $3.13. The company had revenue of $7794.00 million for the quarter, compared to analysts expectations of $8065.42 million. The company’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.94 EPS.

Many Wall Street Analysts have commented on Gilead Sciences. Gabelli & Co Initiated Gilead Sciences on Jun 1, 2016 to “Buy”, Price Target of the shares are set at $109.Gilead Sciences was Downgraded by Maxim Group to ” Hold” on Apr 29, 2016. Shares were Reiterated by UBS on Apr 29, 2016 to “Buy” and Lowered the Price Target to $ 118 from a previous price target of $130 .

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Gilead Sciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Gilead Sciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.